Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
The Department of Justice ended its investigation into Pfizer for possible bribery after Pam Bondi, who previously worked as a consultant for Pfizer, was appointed Attorney General. Follow: @AFpost https://t.co/QY9gdKDOOJ
🇺🇸 DID TRUMP’S DOJ GIVE PFIZER A FREE PASS? Pam Bondi used to work for Pfizer. Then she became Attorney General and suddenly DOJ’s corruption probe into Pfizer vanished from their reports. On day one, Bondi changed DOJ policy to go easier on foreign corruption cases. Five days https://t.co/rklsBSUJAx https://t.co/1TXEP9KqkW
🚨BREAKING: Trump’s DOJ just scrapped its foreign-bribery probe into Pfizer, right after new AG Pam Bondi, Pfizer’s former outside counsel, took the reins. From company lawyer to top cop, and the case disappears. Corporate impunity, now in-house at Justice.
The Department of Justice (DOJ) has terminated its investigation into Pfizer concerning possible foreign bribery allegations following the appointment of Pam Bondi as Attorney General. Bondi previously served as outside counsel and consultant for Pfizer. Shortly after she assumed office, the DOJ paused new foreign corruption cases, leading to the discontinuation of the probe into Pfizer. This policy shift has been noted by legal analysts, including Jarrett Dietrle of the Manhattan Institute, who described the pause on the Foreign Corrupt Practices Act (FCPA) enforcement as a strategic move that may place U.S. firms at a global disadvantage. The case's closure has raised concerns about corporate accountability and the influence of prior professional relationships within the DOJ.
